Showing 6051-6060 of 7681 results for "".
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- Dupixent Performs Well in Phase 3s for Prurigo Nodularishttps://practicaldermatology.com/news/dupixent-performs-well-in-phase-3s-for-prurigo-nodularis/2461138/Detailed positive results from the Phase 3 PRIME2 trial show Dupixent® (dupilumab) significantly reduced itch and skin lesions compared to placebo in adults with uncontrolled prurigo nodularis. Findings were presented in a late-breaking session at the American Academy of Dermat
- Phase 3 Data: Sun Pharma’s Winlevi Is Safe and Effective Acne Txhttps://practicaldermatology.com/news/phase-3-data-sun-pharmas-winlevi-is-safe-and-effective-acne-tx/2461134/Results from two Phase 3 pivotal clinical trials showed favorable safety and efficacy data for Winlevi (clascoterone) cream 1% in patients with acne aged 12 years and older. The findings were presented at the American Academy of Dermatol
- Tremfya Safe, Effective Across Broad Patient Subpopulations Through 5 Years: Analysishttps://practicaldermatology.com/news/tremfya-safe-effective-across-broad-patient-subpopulations-through-five-years-analysis/2461130/Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson can provide a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO), based on an
- Galderma Launches Twyneo in the UShttps://practicaldermatology.com/news/galderma-launches-twyneo-in-the-us/2461128/Galderma has launched Twyneo (tretinoin and benzoyl peroxide) Cream, 0.1%/3% in the US. The launch takes place during the annual meeting of the American Academy of Dermatology (AAD) Annual Meeting. Twyneo Cream features patented microencapsulation technology t
- Mark D. Kaufmann, MD, FAAD Takes the Helm at AADhttps://practicaldermatology.com/news/mark-d-kaufmann-md-faad-takes-the-helm-at-aad/2461126/Long-time Practical Dermatology® Digital Practice editor Mark D. Kaufmann, MD, FAAD, is the new President of the American Academy of Dermatology. Dr. Kaufmann, a clinical professor of the Departmen
- Study: Laser Surgery Lawsuits Less Likely with Physician Operatorshttps://practicaldermatology.com/news/study-laser-surgery-lawsuits-less-likely-with-physician-operators/2461113/The majority of liability claims due to a cutaneous laser surgery device between 2012 and 2020 involved a non-physician operator, according to a new study in the March 2022 issue of Dermatologic Surgery. Researchers analyzed cases of liability claims due to a cutaneou
- Novan, Inc. Acquires EPI Healthhttps://practicaldermatology.com/news/novan-inc-acquires-epi-health/2461106/EPI Health is now a Novan Company. The EP Group today announced the acquisition of EPI Health, LLC by Novan, Inc. EPI Health is a leading company in the US dermatology sector with an established sales force and commercial team with existing, deep market relationships across the de